Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition… Read more
Hanmi Science (008930) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.020x
Based on the latest financial reports, Hanmi Science (008930) has a cash flow conversion efficiency ratio of 0.020x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩18.37 Billion) by net assets (₩921.90 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hanmi Science - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Hanmi Science's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hanmi Science Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hanmi Science ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guizhou Chitianhua Co Ltd
SHG:600227
|
0.047x |
|
PT Vale Indonesia Tbk
F:XT3B
|
0.044x |
|
Godawari Power And Ispat limited
NSE:GPIL
|
0.076x |
|
u-blox Holding AG
PINK:UBLXF
|
0.021x |
|
SMU S.A
SN:SMU
|
0.071x |
|
Marten Transport Ltd
NASDAQ:MRTN
|
0.007x |
|
SKURF
PINK:SKURF
|
N/A |
|
Terna Energy Societe Anonyme Commercial Technical Company
PINK:TREAF
|
0.086x |
Annual Cash Flow Conversion Efficiency for Hanmi Science (2000–2024)
The table below shows the annual cash flow conversion efficiency of Hanmi Science from 2000 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩838.70 Billion | ₩82.99 Billion | 0.099x | +121.62% |
| 2023-12-31 | ₩787.47 Billion | ₩35.16 Billion | 0.045x | +242.35% |
| 2022-12-31 | ₩724.75 Billion | ₩9.45 Billion | 0.013x | -34.24% |
| 2021-12-31 | ₩690.29 Billion | ₩13.69 Billion | 0.020x | -5.45% |
| 2020-12-31 | ₩658.73 Billion | ₩13.82 Billion | 0.021x | +3.99% |
| 2019-12-31 | ₩645.69 Billion | ₩13.02 Billion | 0.020x | +387.66% |
| 2018-12-31 | ₩653.09 Billion | ₩2.70 Billion | 0.004x | +108.17% |
| 2017-12-31 | ₩665.15 Billion | ₩-33.68 Billion | -0.051x | -142.85% |
| 2016-12-31 | ₩647.56 Billion | ₩76.52 Billion | 0.118x | +47.12% |
| 2015-12-31 | ₩584.25 Billion | ₩46.93 Billion | 0.080x | +539.61% |
| 2014-12-31 | ₩417.71 Billion | ₩5.25 Billion | 0.013x | +2287.90% |
| 2013-12-31 | ₩409.07 Billion | ₩-234.79 Million | -0.001x | -100.95% |
| 2010-12-31 | ₩604.83 Billion | ₩36.49 Billion | 0.060x | -55.95% |
| 2009-12-31 | ₩444.88 Billion | ₩60.93 Billion | 0.137x | +31.54% |
| 2008-12-31 | ₩393.00 Billion | ₩40.92 Billion | 0.104x | -48.66% |
| 2006-12-31 | ₩291.16 Billion | ₩59.05 Billion | 0.203x | -4.83% |
| 2005-12-31 | ₩219.66 Billion | ₩46.81 Billion | 0.213x | +53.31% |
| 2004-12-31 | ₩181.81 Billion | ₩25.27 Billion | 0.139x | -4.75% |
| 2003-12-31 | ₩155.62 Billion | ₩22.71 Billion | 0.146x | -34.08% |
| 2002-12-31 | ₩146.43 Billion | ₩32.42 Billion | 0.221x | -22.75% |
| 2001-12-31 | ₩131.69 Billion | ₩37.74 Billion | 0.287x | +39.40% |
| 2000-12-31 | ₩90.93 Billion | ₩18.69 Billion | 0.206x | -- |